Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nu Skin Enterprises, Inc. NUS
$36.84
-$0.73 (-1.97%)
На 18:00, 12 мая 2023
-7.71%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
1868953485.00000000
-
week52high
47.84
-
week52low
29.96
-
Revenue
2225659000
-
P/E TTM
18
-
Beta
1.20588200
-
EPS
2.07000000
-
Last Dividend
1.56000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| DA Davidson | Neutral | Neutral | 23 авг 2022 г. |
| Citigroup | Neutral | Neutral | 08 авг 2022 г. |
| DA Davidson | Neutral | Neutral | 05 мая 2022 г. |
| DA Davidson | Neutral | Neutral | 17 февр 2022 г. |
| Citigroup | Neutral | Neutral | 24 ноя 2021 г. |
| Citigroup | Neutral | Neutral | 05 окт 2022 г. |
| DA Davidson | Neutral | Neutral | 23 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LIPMAN ANDREW D | D | 65393 | 1000 | 23 янв 2023 г. |
| LIPMAN ANDREW D | D | 66393 | 1000 | 22 дек 2022 г. |
| Clark Chayce David | A | 84591 | 61836 | 20 дек 2022 г. |
| CHANG JOSEPH Y | D | 0 | 6800 | 18 дек 2022 г. |
| CHANG JOSEPH Y | D | 23215 | 6542 | 18 дек 2022 г. |
| CHANG JOSEPH Y | A | 29757 | 6800 | 18 дек 2022 г. |
| WOODBURY EDWINA D | A | 16709 | 14 | 07 дек 2022 г. |
| NAPIERSKI RYAN S | D | 19000 | 13000 | 25 ноя 2022 г. |
| NAPIERSKI RYAN S | D | 0 | 12000 | 25 ноя 2022 г. |
| NAPIERSKI RYAN S | D | 122683 | 25000 | 25 ноя 2022 г. |
Новостная лента
Nu Skin (NUS) Q1 Earnings & Revenues Top Estimates, Dip Y/Y
Zacks Investment Research
04 мая 2023 г. в 12:12
Nu Skin's (NUS) first-quarter 2023 results reflect difficult year-over-year comparisons and macroeconomic hurdles. However, a focus on the Nu Vision 2025 strategy has been working well.
Nu Skin Enterprises (NUS) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 19:46
Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.76 per share a year ago.
Factors to Consider Ahead of Nu Skin's (NUS) Q1 Earnings
Zacks Investment Research
01 мая 2023 г. в 12:10
Nu Skin's (NUS) first-quarter performance is likely to reflect macro headwinds like prolonged COVID-related disruptions, unfavorable currency rates and global inflation.
Is Nu Skin Enterprises (NUS) Stock Undervalued Right Now?
Zacks Investment Research
27 апр 2023 г. в 11:27
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Nu Skin's (NUS) Nu Vision 2025 Strategy Bodes Well, Costs Hurt
Zacks Investment Research
18 апр 2023 г. в 10:42
Nu Skin (NUS) benefits from its product launches and Nu Vision 2025 strategy amid challenges like cost inflation and currency volatility.